Regeneron Pharmaceuticals Inc.
REGN,
said late Friday that Chief Financial Officer Robert E. Landry will retire in February, and Christopher Fenimore, the pharma company’s current head of accounting and controller, will succeed Landry upon his retirement. Fenimore joined the company in 2003, Regeneron said. Shares of Regeneron rose 0.5% in the extended session Friday after ending the regular trading day up 0.7%.
Read the full article here
